➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Harvard Business School
McKinsey
McKesson
Johnson and Johnson

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,187,632


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,187,632 protect, and when does it expire?

Patent 8,187,632 protects CIPRO XR and is included in one NDA.

Protection for CIPRO XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-two patent family members in forty countries.

Summary for Patent: 8,187,632
Title:Sustained-release preparations of quinolone antibiotics
Abstract: The present invention relates to an orally administrable preparation comprising a quinolone antibiotic which releases the active compound with a delay.
Inventor(s): Kanikanti; Venkata-Rangarao (Leverkusen, DE), Rupp; Roland (Bergisch Gladbach, DE), Weber; Wolfgang (Cologne, DE), Deuringer; Peter (Cologne, DE), Henck; Jan-Olav (Willich, DE), Stab; Heino (Cologne, DE), Nishioka; Takaaki (Nabari, JP), Katakawa; Yoshifumi (Kusatsu, JP), Taniguchi; Chika (Nishinomiya, JP), Ichihashi; Hitoshi (Suita, JP)
Assignee: Bayer Schering Pharma AG (Leverkusen, DE)
Application Number:11/762,831
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 8,187,632

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Hlthcare CIPRO XR ciprofloxacin; ciprofloxacin hydrochloride TABLET, EXTENDED RELEASE;ORAL 021473-001 Dec 13, 2002 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Bayer Hlthcare CIPRO XR ciprofloxacin; ciprofloxacin hydrochloride TABLET, EXTENDED RELEASE;ORAL 021473-002 Aug 28, 2003 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,187,632

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany100 31 043Jun 26, 2000

International Family Members for US Patent 8,187,632

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 029688 ⤷  Free Forever Trial
Austria 355062 ⤷  Free Forever Trial
Australia 7057301 ⤷  Free Forever Trial
Bulgaria 107372 ⤷  Free Forever Trial
Bulgaria 65914 ⤷  Free Forever Trial
Brazil 0111911 ⤷  Free Forever Trial
Brazil PI0111911 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Harvard Business School
Boehringer Ingelheim
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.